This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zlock, D. W. Articles by Gardner, D. G. Search for Related Content PubMed PubMed Citation Articles by Zlock, D. W. Articles by Gardner, D. G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB 12-O-TETRADECANOYLPHORBOL-13-ACETATE CYCLOHEXIMIDE

(Hypertension. 1997;29:83.)
© 1997 American Heart Association, Inc.

Research Articles (Issue 1, Part 1)

Thrombin Inhibits Atrial Natriuretic Peptide Receptor Activity in Cultured Bovine Endothelial Cells

Douglas W. Zlock; Li Cao; Jianming Wu; David G. Gardner

the Metabolic Research Unit and Department of Medicine, University of California at San Francisco.

Correspondence to David G. Gardner, Box 0540 1141 HSW, Metabolic Research Unit, University of California, San Francisco, CA 94143.

Thrombin and the atrial natriuretic peptide (ANP) possess a number of functionally antagonistic properties in vascular endothelial cells. Thus, regulatory interactions that modulate the activity of one or the other could have important sequelae with regard to cardiovascular homeostasis. Thrombin treatment effected a dose- and time-dependent reduction in ANP receptor activity (maximal 70% to 80% inhibition) in cultured bovine aortic endothelial cells. This resulted from a decrease in total receptor number as well as a modest reduction in the affinity of the receptor for its ligand. The inhibition was largely confined to the type C receptor population, in that thrombin had no effect on maximal type A receptor–linked cGMP accumulation. The protein kinase C–activating phorbol ester 12-O-tetradecanoylphorbol 13-acetate effected a similar reduction in binding activity; however, suppression of protein kinase C activity did not reverse the thrombin effect. Pretreatment of endothelial cells with cycloheximide did not completely prevent the thrombin-dependent inhibition, and thrombin did not effect a reduction in type C receptor mRNA levels, findings that argue for a postsynthetic inhibitory locus. The inhibition of receptor activity was effectively irreversible in that suspension of protein synthesis blocked the recovery of receptor density on the cell surface. Reduction in type C receptor density was accompanied by modest increases in the stability of ANP in the culture medium and enhancement of the cellular cGMP response to the peptide, particularly at low ligand concentrations. These findings demonstrate a potentially important interaction between these two agonist systems in regulating endothelial cell function within the vascular wall.

Key Words: atrial natriuretic factor • thrombin • receptors, atrial natriuretic factor • endothelium

This article has been cited by other articles:

				S. E. Abbey and L. R. Potter Vasopressin-dependent Inhibition of the C-type Natriuretic Peptide Receptor, NPR-B/GC-B, Requires Elevated Intracellular Calcium Concentrations J. Biol. Chem., November 1, 2002; 277(45): 42423 - 42430. [Abstract] [Full Text] [PDF]

				S. Placier, X. Bretot, N. Ardaillou, J.-C. Dussaule, and R. Ardaillou Regulation of ANP clearance receptors by EGF in mesangial cells from NOD mice Am J Physiol Renal Physiol, August 1, 2001; 281(2): F244 - F254. [Abstract] [Full Text] [PDF]